Advances in understanding molecular determinants in FeLV pathology.
Feline leukemia virus (FeLV) occurs in nature not as a single genomic species but as a family of closely related viruses. The disease outcome of natural FeLV infection is variable and likely reflects genetic variation both in the virus and the naturally outbreeding host population. A series of studies have been undertaken with the objectives of examining natural FeLV genetic variation, the selective pressures operative in FeLV infection that lead to predominance of natural variants, and the consequences for infection and disease progression. Genetic variation among FeLV isolates was examined in a cohort of naturally infected cats with thymic lymphoma of T-cell origin, non-T-cell multicentric lymphoma, myeloproliferative disorder or anemia. The predominant isolate in the cohort, designated FeLV-945, was identified exclusively in disorders of non-T-cell origin. The FeLV-945 LTR was shown to contain a unique 21-bp repeat element, triplicated in tandem downstream of enhancer. The 21-bp triplication was shown to act as a transcriptional enhancer and to confer a replicative advantage through the assembly of a distinctive transcription factor complex. Oncogene utilization during tumor induction by FeLV-945 was studied using a recombinant Moloney murine leukemia virus containing the FeLV-945 LTR. This approach identified novel loci of common proviral integration in tumors, including the regulatory subunit of PI-3Kgamma. Mutational changes identified in FeLV-945 SU were shown not to alter receptor usage as measured by host range and superinfection interference, but to significantly increase the efficiency of receptor binding. To determine whether the unique sequence elements of FeLV-945 influence the course of infection and disease in vivo, recombinant viruses were constructed in which the FeLV-945 LTR alone, or the FeLV-945 SU gene and LTR were substituted into the prototype isolate FeLV-A/61E. Longitudinal studies of infected animals showed that substitution of the FeLV-945 LTR into FeLV-A/61E resulted in a significantly more rapid disease onset, but did not alter the tumorigenic spectrum. In contrast, substitution of both the FeLV-945 LTR and SU gene changed the disease outcome entirely. Together, these observations indicate that the distinctive LTR and SU gene of FeLV-945 mediate a rapid pathogenesis with distinctive clinical features and oncogenic mechanisms.
Levy
Laura S
LS
Department of Microbiology and Immunology and Tulane Cancer Center, Tulane University School of Medicine, 1430 Tulane Avenue SL-38, New Orleans, LA 70112, USA. llevy@tulane.edu
D000818:Animals; D002371:Cat Diseases / Q000821:virology*; D002415:Cats; D014644:Genetic Variation; D005256:Leukemia Virus, Feline / Q000235:genetics*; D009154:Mutation; D012192:Retroviridae Infections / Q000662:veterinary* / Q000821:virology*; D012641:Selection, Genetic; D020079:Terminal Repeat Sequences; D014158:Transcription, Genetic; D014412:Tumor Virus Infections / Q000662:veterinary* / Q000821:virology*; D014759:Viral Envelope Proteins / Q000235:genetics
D014759:Viral Envelope Proteins